CN106511579A - Medicine composition for treating gynecological diseases and the like - Google Patents
Medicine composition for treating gynecological diseases and the like Download PDFInfo
- Publication number
- CN106511579A CN106511579A CN201611131886.9A CN201611131886A CN106511579A CN 106511579 A CN106511579 A CN 106511579A CN 201611131886 A CN201611131886 A CN 201611131886A CN 106511579 A CN106511579 A CN 106511579A
- Authority
- CN
- China
- Prior art keywords
- cornu cervi
- pharmaceutical composition
- parts
- salicis babylonicae
- folium salicis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicine composition. By using the matching, the medicine composition has the obvious treatment effects on mastitis, hyperplasia of mammary glands, breast mass, thyroid nodule, hysteromyoma and cyst; and the tumor inhibition effect is achieved. Particularly, the medicine ingredients of the medicine composition consist of deer horn (deer horn discs), inonotusobliquus and willow leaves.
Description
Technical field
The invention belongs to drug regimen preparation field, especially, is related to swell for treating mastitis, cyclomastopathy, mammary gland
Block, thyroid nodule, hysteromyoma, cyst, the preparation of the pharmaceutical composition of function of tumor inhibition.
Background technology
Breast disease is to endanger one of principal disease of women's health at this stage.Chinese population association is issued in Beijing《In
State's mastopathy investigation report》Show that the mortality rate of breast carcinoma in China city increases 38.91%.. breast carcinoma and become right
WomanHealth threatens maximum disease, breast cancer incidence to occupy first of big city female tumor.In asymptomatic women people
Group in, various mastopathy patients reach unexpectedly 52.4%.. this morbidity number be much higher than other chronic commonly encountered diseases of women and account for head
Position.The women's number for wherein only suffering from cyclomastopathy is up to 49.7%.
Thyroid disease is main common to have hyperthyroidism abbreviation hyperthyroidism, thyroid hypofunction referred to as
First is low or hypothyroidism, thyroid tumor, thyroiditiss, thyroid cyst, hyperthyroidism complication etc..Thyroid be human body most
Big endocrine gland.Brownish red, is divided to or so two leaves, middle connected (title isthmus), in " H " shape, about 20～30 grams.Thyroid is located at
The front side of hypolarynx upper tracheal, can move up and down with throat when swallowing.Thyroid basic component unit is acinus, and iodine is had
Very strong aggregation, although the content of iodine generally in body of gland is higher 25～50 times than the content in blood, but daily diet intake
Iodine still have 1/3 to enter thyroid, the 90% of whole body amount of iodine all concentrates on thyroid.Thyroxin is thyroid gland
Hormone.
Hysteropathy refers to the various pathological changes that uterine region occurs, and such as inflammation, damage, tumor and precancerous lesion etc. are
One of modal illness of women.Hysteropathy include endometritis, endometriosis, metrauxe, metropolypuses,
Hysteromyoma, metrocystosis, uterine prolapse, carcinoma of endometrium etc.., there is miscarriage the reason for hysteropathy, takes the uterine cavities such as ring behaviour
Make, and infection etc..
At present Cornu Cervi cowl in terms for the treatment of mammary gland, in terms of thyroid, and uterus in terms of application it is complete not enough, do not have yet
Compatibility is used to optimum formula, simply simple powder that Cornu Cervi cowl is broken into, effect limitation, it is impossible to enough works for playing Cornu Cervi cowl well
With.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition, the compatibility of the pharmaceutical composition is to treating mastitis, mammary gland
Hypertrophy, mammary gland tumor, thyroid nodule, hysteromyoma, cyst effect is significant, function of tumor inhibition, according to relevant scientific research, deer
Angle plays the role of to suppress tumour growth well, using harts horn carbon and Phaeoporus Obliquus, Folium Salicis Babylonicae make powder, granule, electuary, tablet,
The various products such as pill, capsule, oral liquid, meet different demands.
Specifically, the ingredient of the pharmaceutical composition is made up of Cornu Cervi (Cornu Cervi cowl), Phaeoporus Obliquus, Folium Salicis Babylonicae.
Especially：Cornu Cervi (Cornu Cervi cowl) 25-60 parts, Phaeoporus Obliquus press 10-30 parts, Folium Salicis Babylonicae by 10-30 parts.
Preferably, proportion compatibility is 6:1:1
Specifically, the preparation method and dosage form of pharmaceutical composition of the present invention includes：
Cornu Cervi (Cornu Cervi cowl), Phaeoporus Obliquus, Folium Salicis Babylonicae are beaten into powder, electuary, or pill, tablet, oral liquid, capsule, powder is made
Deng.
Especially, the unit dose of pharmaceutical composition of the present invention is 2g/ parts, and instructions of taking is：1 part every time, daily 2-4
It is secondary.
Especially, the oral liquor of pharmaceutical composition of the present invention is：
Cornu Cervi (Cornu Cervi cowl), Phaeoporus Obliquus, Folium Salicis Babylonicae beat powder.Cornu Cervi (Cornu Cervi cowl) presses 25-60g, Phaeoporus Obliquus by 10-30g, Folium Salicis Babylonicae
By 10-30g, raw material 200000g mixed above is proportionally taken, add yellow wine 650000ml, soaked 48 hours, stir for every eight hours
Mix once, filter afterwards, after filtration, add 150000g sucrose, stirring to soak 12 hours, filter, fill is gone out into per bottle of 10ml
Bacterium.
Especially, pharmaceutical composition of the present invention takes taboo：The person of getting angry avoids clothes, take forbid with take Rhizoma et radix veratri (Radix Rhizoma Veratri), Herba portulacae,
Lasiosphaera Seu Calvatia.Avoid taking stimulating food during taking.
The medicinal explanation of each component drugs of pharmaceutical composition of the present invention：
Phaeoporus Obliquus：Phaeoporus obliquus contain betulic acid, and this material can suppress 293 type cancerous cell up to 70%, with very strong
Antitumor activity, and have no toxic side effect.It is main by suppressing the biosynthesiss and resisting mitosis of protein affecting tumor cell
Merisis, and inducing apoptosis of tumour cell and play antitumor action.Cancer cell metastasis, recurrence can be prevented, for coordinating
The radiotherapy of malignant tumor patient, chemotherapy, strengthen the toleration of patient, mitigate toxic and side effects.
Folium Salicis Babylonicae：Heat clearing away, rash, diuresis, removing toxic substances.Control acute diseases such as cholera and sunstroke rash to send out thoroughly not freely, from turbid, furuncle furuncle and phyma, mastitis, thyroid
Swollen, erysipelas, scald, toothache.Dictionary of medicinal plant is recorded：【Clinical report】Treatment inflammation infection upper respiratory tract infection, tracheitiies, lung
The various inflammation such as inflammation, furuncle and phyma, cystitis, pyogenic parotitises, mastitis, pharyngolaryngitis, as a result cure and account for 89.1%.Treatment place
Property goiter
Specific embodiment
Embodiment 1
Choose 25 parts of Cornu Cervi (Cornu Cervi cowl), Phaeoporus Obliquus and 10 parts are pressed by 10 parts, Folium Salicis Babylonicae, add the adjuvant for making electuary, make 2
Gram a finished product electuary.
Embodiment 2
Choose 60 parts of Cornu Cervi (Cornu Cervi cowl), Phaeoporus Obliquus and 30 parts are pressed by 30 parts, Folium Salicis Babylonicae, add the adjuvant for making tablet, make 2
Gram a finished tablet.
Embodiment 3
Choose 60 parts of Cornu Cervi (Cornu Cervi cowl), Phaeoporus Obliquus and 10 parts are pressed by 10 parts, Folium Salicis Babylonicae, add the adjuvant for making electuary, make 2
Gram a finished product electuary.
Embodiment 4
Choose 40 parts of Cornu Cervi (Cornu Cervi cowl), Phaeoporus Obliquus and 20 parts are pressed by 25 parts, Folium Salicis Babylonicae, add the adjuvant for making electuary, make 2
Gram a finished product electuary.
Embodiment 5
Effect experimental
Mammary gland increases scorching：It is adapted to the crowd of all acute mastitiss and chronic mastitiss disease, cure rate general 96%.
Cyclomastopathy:It is adapted to the crowd of all cyclomastopathy diseases, cure rate general 95%.
Breast nodule, lump：It is adapted to all breast nodule, the crowd of lump disease, cure rate general 92%.
Hysteromyoma：It is adapted to the women of all hysteromyoma, cure rate general 95%.
Ovarian cyst：It is adapted to the women of all hysteromyoma, cure rate general 95%.
Cornu Cervi (Cornu Cervi cowl) presses 25-60g, Phaeoporus Obliquus by 10-30g, and Folium Salicis Babylonicae is pressed 10-30g and adds the adjuvant for making electuary, system
Into 2 grams of a finished product electuaries or powder (also can make other preparations in proportion),
30 for the treatment of acute mastitiss age of sucking, symptom has：Mammary gland swelling, redness, whole body heating, mastalgia can not
Touching, wbc value height etc., it is 1 part every time, daily 3-4 time, two days later heating paresthesia disappear, breast can touch remove, it is red after three days
It is swollen to disappear, continuously take 6 to 15 days symptoms completely without, except 2 medications 2 days are invalid use other drugs instead in addition to, the rest is all cured.
Treatment cyclomastopathy, three times a day, treats 28, cures 25 people by 1 part every time.Treatment breast nodule, lump, every time
1 part, three times a day, 25 are treated, wherein 5 people's tuberositys diminish, and remaining all eliminates.
Treatment hysteromyoma, three times a day, treats 18, gradually change of wherein 5 muscular tumors in 3.0cm-5.5cm by 1 part every time
It is little, all cure in 13 people of 0.1-3.0.
Treatment ovarian cyst, three times a day, treats 20, cures 17 by 1 part every time.
Cornu Cervi (Cornu Cervi cowl) presses 25-60g, Phaeoporus Obliquus by 10-30g, Folium Salicis Babylonicae by 10-30g, adds the adjuvant for making electuary,
2 grams of a finished product electuaries or powder (also can make other preparations in proportion) is made,
Treatment breast nodule, lump, three times a day, treat 20 by 1 part every time, and wherein 2 people's tuberositys diminish, and remaining whole disappears
Remove.
Treatment hysteromyoma, 1 part every time, three times a day, treat 15, wherein 2 people's muscular tumors in 4.5cm-5.5cm gradually
Diminish, 13 people of 0.1-4.5 all cure.And find to patient that is multiple, performing the operation repeatedly for several times, it is postoperative to have taken suppression
Muscular tumor growth.Treatment ovarian cyst, three times a day, treats 10, continuously takes 5 to 30 days, cure 9 by 1 part every time.
Treatment acute mastitiss, daily 3 to 4 times, treat 28 by 1 part every time, and in addition to 1 is not adhered to taking, the rest is complete
Portion cures.
Typical case
(1) Mrs Li, 49 years old, in March, 2015 checked the ovarian cyst of 53.4mm*36.8mm*46.8mm, March 20
Day starts to take this formulation product, checks after one and a half months, and 21.3mm*18.2mm*19.6mm, after continuing to take one and a half months
Check, cyst disappears.
(2) Mrs Ding, 30 years old, in September, 2014 checked bilateral breast hypertrophy, and October starts to take above formulation product,
Check after taking one month, without hyperplastic conditions.
(3) Mrs Xu, 44 years old, in April, 2013 checked that double breasts have breast nodule lump, and 9mm*8mm, 6mm*8mm take
Check after one and a half months, 3mm*2mm, 1mm*1.5mm continue to take one month, check that tuberosity disappears.
Claims (4)
1. a kind of pharmaceutical composition for treating gynaecopathia etc., it is characterised in that ingredient by Cornu Cervi (Cornu Cervi cowl), Phaeoporus Obliquus,
Folium Salicis Babylonicae is constituted.
2. a kind of pharmaceutical composition as claimed in claim 1, wherein Cornu Cervi (Cornu Cervi cowl) 25-60 parts, Phaeoporus Obliquus press 10-30
Part, Folium Salicis Babylonicae press 10-30 parts.
3. a kind of pharmaceutical composition as claimed in claim 2, wherein ingredient proportion compatibility are 6:1:1
4. a kind of preparation method of the pharmaceutical composition as described in claim 1-3, including step：Cornu Cervi (Cornu Cervi cowl) presses 25-
60g, Phaeoporus Obliquus press 10-30g, Folium Salicis Babylonicae by 10-30g, proportionally take raw material 200000g mixed above, add yellow wine
650000ml, soaks 48 hours, stirs for every eight hours once, filters afterwards, adds 150000g sucrose, stirring, immersion after filtration
12 hours, filter, fill is into per bottle of 10ml, sterilizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611131886.9A CN106511579A (en) | 2016-12-09 | 2016-12-09 | Medicine composition for treating gynecological diseases and the like |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611131886.9A CN106511579A (en) | 2016-12-09 | 2016-12-09 | Medicine composition for treating gynecological diseases and the like |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106511579A true CN106511579A (en) | 2017-03-22 |
Family
ID=58342901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611131886.9A Pending CN106511579A (en) | 2016-12-09 | 2016-12-09 | Medicine composition for treating gynecological diseases and the like |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511579A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853387A (en) * | 2018-03-29 | 2018-11-23 | 黄静湖 | A kind of set a broken bone osteopathy and the Chinese medicine composition of tumour and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104146310A (en) * | 2013-05-14 | 2014-11-19 | 吕奎荣 | Making method for disease treatment drink |
| CN104905237A (en) * | 2014-03-12 | 2015-09-16 | 李涛 | Inonotus obliquus composite electuary and production method thereof |
-
2016
- 2016-12-09 CN CN201611131886.9A patent/CN106511579A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104146310A (en) * | 2013-05-14 | 2014-11-19 | 吕奎荣 | Making method for disease treatment drink |
| CN104905237A (en) * | 2014-03-12 | 2015-09-16 | 李涛 | Inonotus obliquus composite electuary and production method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 林成连: "中药治疗急性乳腺炎48例", 《现代实用医学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853387A (en) * | 2018-03-29 | 2018-11-23 | 黄静湖 | A kind of set a broken bone osteopathy and the Chinese medicine composition of tumour and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103861079A (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN106421383A (en) | Anticancer traditional Chinese medicine composition | |
| CN103920034A (en) | Traditional Chinese medicine composition for alleviating side effects of chemotherapy of cancer patient and preparation method traditional Chinese medicine composition | |
| CN103495048A (en) | Traditional Chinese medicine composition for treating children's aphthous stomatitis | |
| CN104383244B (en) | It is a kind of to treat Chinese medicine composition of cancer of the esophagus and preparation method thereof | |
| CN106511579A (en) | Medicine composition for treating gynecological diseases and the like | |
| CN101991804B (en) | Externally applied medicament for treating stomach illness | |
| CN101543616A (en) | Traditional Chinese medicine composition for preventing and treating tumor and its preparation method | |
| CN103705870A (en) | Traditional Chinese medicine composition for treating mastitis | |
| CN102106999A (en) | Chinese medicinal compound preparation for treating dysphagia due to stroke and preparation method thereof | |
| CN101961455A (en) | Traditional Chinese medicine for treating chronic colitis disease | |
| CN111135270A (en) | A Chinese medicinal composition for treating female hyperplasia of mammary glands due to stagnation of qi and stagnation of liver-qi and stagnation of phlegm and blood stasis | |
| CN103301281B (en) | Traditional Chinese medicine for treating uterine fibroid and preparation method thereof | |
| CN203029653U (en) | Chinese patent medicine pill resistant to gastrointestinal tumors | |
| CN102626506B (en) | Traditional Chinese medicine for curing seroperitoneum | |
| CN109999143B (en) | Traditional Chinese medicine for treating benign tumor proliferative diseases | |
| CN105194577A (en) | Medicament for treating hyperplasia of mammary glands | |
| CN101461854B (en) | Colitis treating Chinese medicine preparation | |
| CN103816468B (en) | A kind of capsule treating gastric cancer and preparation method thereof | |
| CN105079310A (en) | Traditional Chinese medicine composition for relieving pain and method for preparing traditional Chinese medicine composition | |
| CN103585258A (en) | Traditional Chinese medicine composition for treating breast pain | |
| CN115192662A (en) | Traditional Chinese medicine composition and medicine for treating tumors | |
| CN103495038A (en) | Traditional Chinese medicine formula treating gastroenteric ulcers | |
| CN114129693A (en) | Composition for treating cancer and preparation method and application thereof | |
| CN101890086B (en) | Medicament for treating stomach disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |